Wayne Eskridge:
ORCID: https://orcid.org/0000-0002-9717-5194
Role: Data curationRole: Funding acquisitionRole: InvestigationRole: MethodologyRole:
Project administrationRole: ResourcesRole: SoftwareRole: SupervisionRole: Writing
– review & editing
John M. Vierling:
ORCID: https://orcid.org/0000-0001-5547-6020
Role: Data curationRole: Formal analysisRole: InvestigationRole: MethodologyRole:
ValidationRole: Writing – review & editing
Wayne Gosbee: Role: InvestigationRole: Project administrationRole: ResourcesRole: Supervision
Gabriella A. Wan: Role: Formal analysisRole: SoftwareRole: ValidationRole: VisualizationRole: Writing
– review & editing
May-Linh Hyunh: Role: Formal analysisRole: SoftwareRole: VisualizationRole: Writing – original draft
Henry E. Chang: Role: Writing – review & editing
Daisuke Tokuhara: Role: Editor
Journal ID (nlm-ta): PLoS One
Journal ID (iso-abbrev): PLoS One
Journal ID (publisher-id): plos
Title:
PLoS ONE
Publisher:
Public Library of Science
(San Francisco, CA USA
)
ISSN
(Electronic):
1932-6203
Publication date
(Electronic):
30
November
2021
Publication date Collection: 2021
Volume: 16
Issue: 11
Electronic Location Identifier: e0260320
Affiliations
[1
]
Fatty Liver Foundation, Boise, Idaho, United States of America
[2
]
Section of Gastroenterology and Hepatology and Division of Abdominal Transplantation,
Departments of Medicine and Surgery, Baylor College of Medicine, Houston, Texas, United
States of America
[3
]
Link2Labs, Houston, Texas, United States of America
Osaka City University Graduate School of Medicine, JAPAN
Author notes
Competing Interests: I have read the journal’s policy and the authors of this manuscript have the following
competing interests: WE, GAW, MLH, and HEC are employees of FLF, which reports program
support and educational grants from Allergan, Amazon, Bristol-Myers Squibb, Celgene,
Clinical Care Options, Continuum Clinical, Echosens, Eskridge Family Trust, Fibronostics,
First Line Creative, Gilead Sciences, Global Engage, Google, Health Business Solutions,
Intercept Pharmaceuticals, Madrigal Pharmaceuticals, Meetrix, Merck & Co., Inc. NetNoggin,
Prosciento, Pfizer, Terns Pharmaceuticals and various private and philanthropic individual
donors. JMV reports relevant research and grant support from Allergan, Alnylam, 89Bio,
Bristol-Myers Squibb, Celgene, CymaBay, Exalenz, Galectin, Galmed, Genfit, Gilead,
Hanmi, Immuron, Intercept, Madrigal, Merck, Mochida, Molecular Stethoscope, Novartis,
NovoNordisk, Pliant, Sagimet, Tobira Therapeutics, and Zydus; advisor or consultant
fees from Allergan, Blade Pharmaceuticals, Bristol-Myers Squibb, Conatus, CymaBay,
Exalenz, Fractyl, Intercept, Novartis; and is on the Data Safety and Management Boards
for NIH NIDDK Drug-Induced Liver Injury Network (DILIN) and Fractyl. WG reports grant
support from AbbVie and Gilead Sciences. This does not alter our adherence to PLOS
ONE policies on sharing data and materials.
Author information
Article
Publisher ID:
PONE-D-21-19005
DOI: 10.1371/journal.pone.0260320
PMC ID: 8631660
PubMed ID: 34847156
SO-VID: 95f14d8f-b0ae-42f6-aea2-5aaf12661088
Copyright © © 2021 Eskridge et al
License:
This is an open access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided
the original author and source are credited.
Funded by:
Health Business Solutions
Award Recipient
:
ORCID: https://orcid.org/0000-0002-9717-5194
Wayne Eskridge
Funded by:
Intercept Pharmaceuticals (US)
Award Recipient
:
ORCID: https://orcid.org/0000-0002-9717-5194
Wayne Eskridge
Funded by:
Eskridge Family Trust (US)
Award Recipient
:
ORCID: https://orcid.org/0000-0002-9717-5194
Wayne Eskridge
We received study grants from Intercept Pharmaceuticals (
https://www.interceptpharma.com/) and the Eskridge Family Trust. In-kind contributions were made by Health Business
Solutions. The opinions, results and conclusions reported in this paper are those
of the authors. The funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
Subject:
Research Article
Subject:
Medicine and Health Sciences
Subject:
Pathology and Laboratory Medicine
Subject:
Anatomical Pathology
Subject:
Cytopathology
Subject:
Steatosis
Subject:
Biology and Life Sciences
Subject:
Developmental Biology
Subject:
Fibrosis
Subject:
Medicine and Health Sciences
Subject:
Gastroenterology and Hepatology
Subject:
Liver Diseases
Subject:
Fatty Liver
Subject:
Medicine and Health Sciences
Subject:
Epidemiology
Subject:
Medical Risk Factors
Subject:
Biology and Life Sciences
Subject:
Biochemistry
Subject:
Lipids
Subject:
Fats
Subject:
Medicine and Health Sciences
Subject:
Endocrinology
Subject:
Endocrine Disorders
Subject:
Diabetes Mellitus
Subject:
Medicine and Health Sciences
Subject:
Medical Conditions
Subject:
Metabolic Disorders
Subject:
Diabetes Mellitus
Subject:
Medicine and Health Sciences
Subject:
Medical Conditions
Subject:
Cardiovascular Diseases
Subject:
Cardiovascular Disease Risk
Subject:
Medicine and Health Sciences
Subject:
Cardiology
Subject:
Cardiovascular Medicine
Subject:
Cardiovascular Diseases
Subject:
Cardiovascular Disease Risk
Subject:
Biology and Life Sciences
Subject:
Physiology
Subject:
Physiological Parameters
Subject:
Body Weight
Subject:
Obesity